Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Hui Huang | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. 📚 He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. 🏆 A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. 🔬 His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) 📚. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories 🏅. A recipient of China’s National Science Fund for Excellent Young Scholars 🎓, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❤️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) 🔬🇨🇳. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation 🧠🫀. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages 🌍💰. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes 🚀🩺.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. 🌡️🧠🫀 She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. 📊💻 Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Published on by Top Pharmaceutical

Alessandra Tucci | Personalized Medicine | Women Researcher Award

Dr. Alessandra Tucci, ASST Spedali Civili di Brescia, Italy

Dr. Alessandra Tucci is an esteemed Italian hematologist and Director of the Hematology Unit at ASST Spedali Civili di Brescia. With over three decades of expertise, she specializes in lymphomas, particularly in elderly patients. She holds dual specializations in Allergology & Immunology (University of Florence) and Hematology (University of Milan). A key figure in national and international research, she has led multiple clinical trials and serves on prestigious scientific boards, including the Italian Lymphoma Foundation (FIL) and European Hematology Association (EHA). An accomplished author and peer reviewer, Dr. Tucci continues to advance hematological research.

Publication Profile

Scopus

Education

Dr. Alessandra Tucci 🎓 earned her Doctor of Medicine degree from the University of Brescia in 1987, specializing in Allergology, Immunology, and Hematology. 🩸 Her dual specialization underscores her deep expertise in blood disorders and immune-related conditions. 🏥 Passionate about advancing medical science, she further pursued a Master’s in Management applied to hematology, showcasing her leadership in clinical and research settings. 📚 With a strong foundation in both patient care and scientific innovation, Dr. Tucci continues to make significant contributions to the field, bridging the gap between medical research and practical healthcare solutions. 🔬✨

Experience

Dr. Alessandra Tucci 🔬 is a Principal Investigator in numerous national and international studies, focusing on hematology, particularly lymphomas and hematologic malignancies in elderly patients. 🩸 Her research impact is evident through an impressive H-index of 44 (Scopus) and 48 (Google Scholar), with over 9,792 citations. 📊 She has contributed as a Guest Editor for Special Issues in high-impact journals like Cancers and serves as a reviewer for prestigious publications such as Lancet Haematology and Blood Advances. 📖 Her dedication to advancing hematologic research continues to shape the field and improve patient outcomes worldwide.

Awards

Dr. Alessandra Tucci 🏆 has played a pivotal role in clinical trials (phases I-III), driving innovative treatments in hematology and significantly improving patient care. 🩸 Her contributions extend beyond research, as she actively shapes the scientific community through editorial work, peer reviews, and participation in prestigious scientific boards. 📖🔬 Recognized for her expertise and leadership, she is a respected thought leader whose work influences both clinical practice and future therapeutic advancements. 🌍✨ Through her dedication, Dr. Tucci continues to leave a lasting impact on the field of hematology, inspiring researchers and improving patient outcomes worldwide. 💡👩‍⚕️

Research Focus

Dr. Alessandra Tucci is a distinguished researcher specializing in hematology 🩸, with a focus on lymphomas 🦠, leukemias 🧬, and stem cell transplantation 🏥. Her work extensively explores invasive pulmonary aspergillosis in leukemia, mantle cell lymphoma prognosis, and the impact of radiotherapy on hematologic malignancies. She contributes to clinical trials, geriatric oncology assessments, and advanced imaging techniques like FDG PET/CT 📡 to improve diagnostic precision and treatment outcomes. Dr. Tucci’s research plays a critical role in optimizing chemoimmunotherapy 💉 and personalized medicine for hematologic disorders.

Publication Top Notes

Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda

Impact of the Number of Administered Systemic Treatment Lines on Local Response to Radiation Therapy for Multiple Myeloma

A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ study

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2-[18F]FDG PET/CT in Advanced Mantle Cell Lymphoma

Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study

Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results

Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 (Genome Medicine, (2023), 15, 1, (22), 10.1186/s13073-023-01173-8)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome

Henryk Mazurek | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Henryk Mazurek | Precision Medicine | Best Researcher Award

Prof. Henryk Mazurek, National Tuberculosis and Lung Diseases Institute, Department of Pneumonology and Cystic Fibrosis, Poland

Prof. Henryk Mazurek is a distinguished pulmonologist, allergologist, and pediatrician specializing in pediatric pulmonology and respiratory diseases. He serves as the Head of the Department of Pneumonology and Cystic Fibrosis at the National Tuberculosis and Lung Diseases Institute, Poland 🇵🇱. With over 60 original research articles and extensive contributions to medical literature 📚, he has significantly advanced the understanding of chronic respiratory diseases, asthma, and cystic fibrosis. A member of esteemed scientific societies 🌍, he actively collaborates internationally and leads impactful research projects. His work in AI-assisted diagnostics and pulmonary care is shaping the future of respiratory medicine. 🚀

Publication Profile

Scopus

Professional Background

Professor Henryk Mazurek is a distinguished pulmonary disease specialist, allergologist, pediatrician, and pediatric pulmonology expert 🩺. He completed postgraduate studies in respiratory pathophysiology in France 🇫🇷 and holds the title of Full Professor in medical and health sciences 🎓. As an academic, he teaches nursing and postgraduate medical training in pediatrics, allergology, and lung diseases. He has authored and co-authored over 60 original articles, 100+ textbook chapters, and numerous scientific publications 📚. A sought-after lecturer, he shares his expertise at medical conferences, educating physicians and healthcare professionals worldwide 🌍.

Memberships

Prof. Henryk Mazurek is an esteemed member of several prestigious scientific organizations, fostering international collaboration in respiratory medicine 🌍🫁. He holds a combined membership in the European Respiratory Society (ERS) / Polish Respiratory Society, along with memberships in the Polish Society of Allergology and the Polish Society of Pediatric Pulmonology, where he is an honorary member 🎖️. For many years, he contributed to the Scientific Council of the Institute of Tuberculosis and Lung Diseases in Warsaw 🏥. Additionally, he served on the Main Boards of the Polish Society of Allergology (2015-2021) and the Polish Society of Cystic Fibrosis (2014-2018) 📚.

Industry Projects

Prof. Henryk Mazurek has actively contributed to over 50 industry-sponsored clinical trials, showcasing his expertise in applied research 🔬. His consultancy work plays a crucial role in bridging academic research with real-world healthcare applications, particularly in advancing treatment strategies for cystic fibrosis 🫁. Through his collaborations with pharmaceutical and medical device companies 💊🩺, he has successfully translated research findings into clinical practice, improving patient outcomes. His dedication to innovation and evidence-based solutions continues to shape the future of respiratory medicine, reinforcing his impact on both academia and industry. 🌍

Research Focus

Prof. Henryk Mazurek’s research primarily focuses on respiratory diseases 🫁, particularly in cystic fibrosis 🧬, pediatric pulmonology 👶, and ventilator-associated pneumonia 🏥. His work explores innovative AI-facilitated home monitoring 🤖 for cystic fibrosis, childhood asthma treatments 🌬️, and the effects of medications like Gabapentin on post-operative pain 💊. He has also studied risk factors for pneumonia 🦠 and strategies for its prevention in ventilated patients. His expertise lies in pulmonary infections, inflammatory biomarkers, and personalized medicine 🧑‍⚕️. His contributions significantly impact respiratory healthcare, enhancing diagnostic and therapeutic approaches for both pediatric and adult patients.

Publication Top Notes

AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populations

Childhood asthma treatment based on indirect hyperresponsiveness test: Randomized controlled trial

The Effects of Gabapentin on Post-Operative Pain and Anxiety, Morphine Consumption and Patient Satisfaction in Paediatric Patients Following the Ravitch Procedure—A Randomised, Double-Blind, Placebo-Controlled, Phase 4 Trial

Risk Factors and Protective Factors against Ventilator-Associated Pneumonia—A Single-Center Mixed Prospective and Retrospective Cohort Study

Automatic continuous control of cuff pressure and subglottic secretion suction used together to prevent pneumonia in ventilated patients—a retrospective and prospective cohort study

Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6

Edwin Posadas | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. 📚🔬✨

Publication Profile

orcid

Education

Dr. Edwin Posadas 🎓 began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) 🏥. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. 🔬💙

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) 🏥, Association of Philippine Physicians of America (1998) 🇵🇭, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) 🎖️. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) 🔬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) 🚀 and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine 🏥, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 🧬🎗️. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. 🔬💙

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer 🔬, metastasis 🧬, and nanotechnology-based diagnostics 🏥. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. 🎗️

Publication Top Notes

Determinants of Liver Metastasis

A Nanotechnology Solution for Early Detection of Micrometastatic Prostate Cancer After Radical Prostatectomy

A blood test to identify prostate cancer patients at risk for visceral metastasis

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling

FYN Is a Key Regulator of Metastasis in Prostate Cancer

Targeting FYN in Prostate Cancer: A Key Regulator of Growth and Motility

Prof. Dr. Federico Hawkins|Personalized Medicine|Excellence in Research

Published on by Top Pharmaceutical

Prof. Dr. Federico Hawkins-Personalized Medicine-Excellence in Research

Prof. Dr. Federico Hawkins at Universidad Complutense Madrid ,Spain

Author Profile

Scopus

🎓 Early Academic Pursuits

Federico Gilberto Hawkins Carranza embarked on a remarkable academic journey in the field of medicine, earning his General Physician degree from the University of Salamanca in 1969. This was followed by his pursuit of higher education, where he completed a Ph.D. thesis titled “Mechanism of Action of Gastrointestinal Hormones upon Pancreas” under the mentorship of Prof. Dr. Manuel Serrano Ríos at the University Autónoma of Madrid in 1978.

During this period, Dr. Hawkins also obtained a Diploma in Psychology from the Pontifical University of Salamanca (1969) and completed his Internship and Residency at Fundación Jiménez Díaz (1969–1972), specializing in Internal Medicine and Endocrinology in 1973. His thirst for knowledge led him to prestigious institutions worldwide through scholarships, including the Endocrine Unit at Hammersmith Hospital in London (1977) and the Transplant Unit at Minnesota University (1980).

💼 Professional Endeavors

Dr. Hawkins began his illustrious career as a physician in the Service of Endocrinology at University Hospital 12 de Octubre, Madrid, in 1973. By 1979, he rose to the position of Chief of Service of Endocrinology, a role he held until 2016. His contributions to clinical endocrinology were instrumental in shaping the department into a hub of innovation and excellence.

Parallel to his clinical work, Dr. Hawkins was an active academician. In 1978, he was appointed Professor of Medicine at Complutense University of Madrid and eventually became the Chairman of Medicine in 2000. Post-retirement, he continued to serve as a Consultant at the Research Institute i+12 at University Hospital 12 de Octubre.

🔬 Contributions and Research Focus

Dr. Hawkins made pioneering contributions to endocrinology, focusing on diabetes, thyroid diseases, and postmenopausal osteoporosis.

Diabetes Mellitus:

  • Developed and implemented Radioimmunoassays (RIA) for insulin and glucagon in Spain.
  • Conducted studies on insulin secretion in chromosomal disorders, including Klinefelter’s and Down syndromes.
  • Demonstrated the hypoglycemic effects of fig tree decoctions in animals and humans.

Thyroid Diseases:

  • Advanced the understanding of thyrocalcitonin fractions in neoplasia and thyroid cancer.
  • Investigated the relationship between TSH suppression and bone mass.

Postmenopausal Osteoporosis:

  • Played a key role in clinical trials for drugs such as Alendronate, Risedronate, Teriparatide, and Strontium Ranelate.
  • Actively participated in drafting the Spanish Guide for Osteoporosis, contributing to patient care protocols.

🏆 Accolades and Recognition

Dr. Hawkins’ expertise and leadership were widely acknowledged:

  • He was appointed as an Academician Correspondent at the Royal Academy of Medicine in 2017.
  • Received honorary titles such as Extraordinary Professor at the Faculty of Medicine in Panama (2016).
  • Served as the Director of the Revista Española de Enfermedades Metabólicas and a reviewer for prestigious journals, including Current Medical Research & Opinion.

🌍 Impact and Influence

Dr. Hawkins significantly influenced the global medical community through his research and teaching. His studies on bone mass in diabetics and early markers of bone loss have been foundational in advancing treatment strategies. As an academician, he nurtured generations of physicians and researchers, promoting excellence in clinical endocrinology.

🏛️ Legacy and Future Contributions

Even in retirement, Dr. Hawkins remains a towering figure in endocrinology. His dedication to patient care, innovative research, and teaching has left a lasting legacy. His work on endocrine disorders, especially diabetes and osteoporosis, continues to shape clinical practices worldwide. Dr. Hawkins also actively contributes to medical guidelines and collaborates with researchers globally, ensuring his insights continue to benefit humanity.

Notable Publication

Socioeconomic status, osteoporosis and fragility fractures | Estatus socioeconómico, osteoporosis y fracturas por fragilidad

  • Authors   : Martínez-Díaz-Guerra, G., Hawkins Carranza, F., Librizzi, S.
  • Year         :2024

Health-Related Quality of Life Long-Term Study in Lung Transplant Patients: A Single-Center Experience

      • Authors   : Monteagudo, L.J., Diaz-Guerra, G.M., Badillo, A.Á., … Arriscado, C.M., Hawkins Carranza, F.
      • Year         :2024

Comparison of Bone Mineral Density and Trabecular Bone Score in Patients with and without Vertebral Fractures and Differentiated Thyroid Cancer with Long-Term Serum Thyrotrophin-Suppressed Therapy

  • Authors   : Hawkins Carranza, F., Arroba, C.M.-A., López Alvarez, M.B., Librizzi, S., Martínez Díaz Guerra, G.

Incidence of type 2 diabetes in the elderly in Central Spain: Association with socioeconomic status, educational level, and other risk factors

  • Authors   :Hawkins Carranza, F., Corbatón-Anchuelo, A., Bermejo Pareja, F., … Benito-León, J., Serrano-Ríos, M.
  • Journal     : Primary Care Diabetes
  • Year         :2022                                                                                                                                                                                                                                                                                                                                                                                                           

Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer

  • Authors   :Hawkins Carranza, F., Guadalix Iglesias, S., De Mingo Dominguez, M.L., … Alvares, B.L., Martínez Diaz-Guerra, G.